Business Context and Reporting Period
Company: Tradeweb Markets Inc. (TW)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Tradeweb is a global leader in building and operating electronic marketplaces for institutional, wholesale, retail, and corporate clients across rates, credit, equities, and money markets. The company serves over 3,000 clients in more than 85 countries. In 2024, the company expanded its footprint through the acquisition of r8fin (algorithmic trading technology) in January and Institutional Cash Distributors (ICD) in August, the latter adding a new "corporates" client sector focused on money market funds.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $1,725.9 million | $1,338.2 million | +29.0% |
| Operating Income | $678.0 million | $505.3 million | +34.2% |
| Net Income (GAAP) | $569.9 million | $419.5 million | +35.9% |
| Net Income Attributable to Tradeweb | $501.5 million | $364.9 million | +37.4% |
| Diluted EPS (GAAP) | $2.33 | $1.71 | +36.3% |
| Adjusted EBITDA | $920.6 million | $701.6 million | +31.2% |
| Adjusted EBITDA Margin | 53.3% | 52.4% | +90 bps |
| Free Cash Flow | $808.9 million | $684.3 million | +18.2% |
| Cash and Cash Equivalents | $1,340.3 million | $1,706.5 million | -21.5% |
| Debt Outstanding | $0 | $0 | - |
Note: The decrease in cash and cash equivalents was primarily due to the $773.8 million cash paid for the ICD acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $387.7 million (29.0%), driven by a $345.2 million increase in transaction fees and commissions. This was fueled by higher trading volumes in rates derivatives, U.S. and European corporate bonds, and government bonds, as well as the contribution from the ICD acquisition.
- Asset Class Performance:
- Rates: Revenue grew 30.1% to $904.9 million.
- Credit: Revenue grew 24.9% to $459.0 million.
- Money Markets: Revenue surged 82.9% to $115.2 million, primarily due to the ICD acquisition and higher repurchase agreement volumes.
- Market Data: Revenue grew 25.5% to $118.0 million, driven by increased fees from the LSEG market data agreement.
- Expense Increases: Total expenses rose 25.8% to $1.05 billion. Employee compensation and benefits increased 28.8% due to higher incentive compensation and headcount. Depreciation and amortization increased 18.7% due to assets acquired in the ICD, r8fin, and Yieldbroker acquisitions.
- Acquisitions: The company completed the acquisition of ICD (August 2024) and r8fin (January 2024). ICD contributed $43.2 million in revenue and $2.1 million in operating income for the period from acquisition to year-end.
Guidance, Outlook, and Risks
- Capital Expenditures: The company expects total cash paid for capital expenditures and software development costs for fiscal year 2025 to be between $99 million and $109 million. This represents a 17% increase from 2024, largely due to the global headquarters relocation.
- Dividends: The board declared a quarterly cash dividend of $0.12 per share for Q1 2025, a 20% increase from the $0.10 per share paid in 2024.
- Share Repurchases: As of December 31, 2024, $179.9 million remained available under the 2022 Share Repurchase Program (authorized up to $300 million).
- Key Risks:
- Regulatory Changes: Extensive regulation in the U.S. and internationally (e.g., SEC, CFTC, EU's DORA) could increase compliance costs or restrict business activities. The company is subject to new SEC rules regarding central clearing of Treasury securities.
- Market Volatility: Economic, political, and market conditions can reduce trading volumes. While volatility often increases volume, extreme instability may drive clients to voice trading.
- Cybersecurity: As a technology-dependent financial services firm, the company faces risks from cyber attacks, system failures, and data breaches.
- Concentration Risk: The company relies on a limited number of dealer clients for liquidity and data. Refinitiv (an affiliate of LSEG) controls approximately 89.9% of the combined voting power.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and revenue contribution of the ICD and r8fin acquisitions, specifically the cross-selling potential to existing client bases.
- Tax Receivable Agreement (TRA): Review the $372.8 million liability under the TRA and the impact of future tax basis step-ups on cash flow obligations to Continuing LLC Owners.
- Regulatory Capital: Confirm that regulated subsidiaries continue to maintain sufficient net capital and financial resources above minimum requirements ($83.0 million aggregate requirement as of Dec 31, 2024).
- Failed Settlements: Note the $67.8 million receivable/payable related to failed settlement transactions (primarily U.S. Treasuries) which settled in January 2025; monitor if this becomes a recurring liquidity drain.
- Non-GAAP Reconciliations: Scrutinize the adjustments made to reach Adjusted EBITDA and Adjusted Net Income, particularly regarding stock-based compensation and acquisition-related depreciation.